Company intelligence / Profile preview

Actome

Freiburg im Breisgau, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

Actome developed and commercialized the PICO technology enabling absolute quantification of proteins, protein interactions, post-translational modifications, and extracellular vesicles with ultra-high sensitivity; products were released for commercial use in 2022[2][1]. The company filed for insolvency in July 2025 and its continued operations depend on securing new investment[2].

Modalities: DeviceAssay kit
Industry: Non-Drug Biotech

Partnerships

QIAGEN

Beyond the preview

Go deeper on Actome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actome.

Explore the full profile